Italy's An­geli­ni Phar­ma teams up with JCR on blood-brain bar­ri­er deal

An­geli­ni Phar­ma plans to pay Japan­ese phar­ma JCR Phar­ma­ceu­ti­cals more than $500 mil­lion as part of a re­search col­lab­o­ra­tion that fo­cus­es on the blood-brain bar­ri­er.

The CNS-fo­cused phar­ma com­pa­ny, part of the Ital­ian con­glom­er­ate An­geli­ni In­dus­tries, put out word Thurs­day about the new de­vel­op­ment and com­mer­cial­iza­tion agree­ment, which aims to de­vel­op new treat­ments for epilep­sy.

As part of the de­vel­op­ment and com­mer­cial­iza­tion agree­ment, An­geli­ni will re­im­burse JCR for re­search ex­pens­es and pay an undis­closed up­front pay­ment — along with $505.5 mil­lion in mile­stones, plus roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER